Sophie G Zaloumis

List of Publications by Year
in descending order

44	1,011	430754	454834
papers	citations	18 h-index	30 g-index

48	48	48	1653
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Scoping Review of Antimalarial Drug Candidates in Phase I and II Drug Development. Antimicrobial Agents and Chemotherapy, 2022, 66, AAC0165921.	1.4	8
2	Quantification of the dynamics of antibody response to malaria to inform sero-surveillance in pregnant women. Malaria Journal, 2022, 21, 75.	0.8	7
3	Anti-Gametocyte Antigen Humoral Immunity and Gametocytemia During Treatment of Uncomplicated Falciparum Malaria: A Multi-National Study. Frontiers in Cellular and Infection Microbiology, 2022, 12, 804470.	1.8	1
4	Parasite-Host Dynamics throughout Antimalarial Drug Development Stages Complicate the Translation of Parasite Clearance. Antimicrobial Agents and Chemotherapy, 2021, 65, .	1.4	3
5	Community-based molecular and serological surveillance of subclinical malaria in Myanmar. BMC Medicine, 2021, 19, 121.	2.3	6
6	Development and Validation of an In Silico Decision Tool To Guide Optimization of Intravenous Artesunate Dosing Regimens for Severe Falciparum Malaria Patients. Antimicrobial Agents and Chemotherapy, 2021, 65, .	1.4	1
7	Seeking an optimal dosing regimen for OZ439/DSM265 combination therapy for treating uncomplicated falciparum malaria. Journal of Antimicrobial Chemotherapy, 2021, 76, 2325-2334.	1.3	8
8	Utilising surface-level data to explore surface, tooth, individual and family influence on the aetiology of hypomineralised second primary molars. Journal of Dentistry, 2021, 113, 103797.	1.7	1
9	Artemisinin Resistance and the Unique Selection Pressure of a Short-acting Antimalarial. Trends in Parasitology, 2020, 36, 884-887.	1.5	19
10	Transient childhood wheeze is associated with less atopy in adolescence. Pediatric Allergy and Immunology, 2020, 31, 913-919.	1.1	2
11	Malaria Parasite Clearance: What Are We Really Measuring?. Trends in Parasitology, 2020, 36, 413-426.	1.5	21
12	Sequential infection experiments for quantifying innate and adaptive immunity during influenza infection. PLoS Computational Biology, 2019, 15, e1006568.	1.5	9
13	Contribution of Functional Antimalarial Immunity to Measures of Parasite Clearance in Therapeutic Efficacy Studies of Artemisinin Derivatives. Journal of Infectious Diseases, 2019, 220, 1178-1187.	1.9	21
14	Differential impact of malaria control interventions on P. falciparum and P. vivax infections in young Papua New Guinean children. BMC Medicine, 2019, 17, 220.	2.3	19
15	Modeling the dynamics of Plasmodium falciparum gametocytes in humans during malaria infection. ELife, 2019, 8, .	2.8	36
16	In Silico Investigation of the Decline in Clinical Efficacy of Artemisinin Combination Therapies Due to Increasing Artemisinin and Partner Drug Resistance. Antimicrobial Agents and Chemotherapy, 2018, 62, .	1.4	4
17	Investigating the Efficacy of Triple Artemisinin-Based Combination Therapies for Treating Plasmodium falciparum Malaria Patients Using Mathematical Modeling. Antimicrobial Agents and Chemotherapy, 2018, 62, .	1.4	43
18	New Mathematical Models of Antimalarial Drug Action to Improve Drug Dosing Regimens. Mathematics for Industry, 2018, , 7-11.	0.4	0

#	Article	IF	Citations
19	A Dynamic Stress Model Explains the Delayed Drug Effect in Artemisinin Treatment of Plasmodium falciparum. Antimicrobial Agents and Chemotherapy, 2017, 61, .	1.4	9
20	A mechanistic model quantifies artemisinin-induced parasite growth retardation in blood-stage Plasmodium falciparum infection. Journal of Theoretical Biology, 2017, 430, 117-127.	0.8	9
21	HFE p.C282Y homozygosity predisposes to rapid serum ferritin rise after menopause: A genotypeâ€stratified cohort study of hemochromatosis in Australian women. Journal of Gastroenterology and Hepatology (Australia), 2017, 32, 797-802.	1.4	16
22	Analysis of ex vivo drug response data of Plasmodium clinical isolates: the pros and cons of different computer programs and online platforms. Malaria Journal, 2016, 15, 137.	0.8	12
23	Heightened self-reactivity associated with selective survival, but not expansion, of naÃ¯ve virus-specific CD8 ⁺ T cells in aged mice. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 1333-1338.	3.3	45
24	Presenting parasitological data: the good, the bad and the error bar. Parasitology, 2015, 142, 1351-1363.	0.7	0
25	Intervals to Plasmodium falciparum recurrence after anti-malarial treatment in pregnancy: a longitudinal prospective cohort. Malaria Journal, 2015, 14, 221.	0.8	13
26	Modelling the time course of antimalarial parasite killing: a tour of animal and human models, translation and challenges. British Journal of Clinical Pharmacology, 2015, 79, 97-107.	1.1	13
27	Nonâ€proportional odds multivariate logistic regression of ordinal family data. Biometrical Journal, 2015, 57, 286-303.	0.6	4
28	Natural history of <scp>HFE</scp> simple heterozygosity for <scp>C</scp>282<scp>Y</scp> and <scp>H</scp>63<scp>D</scp>: A prospective 12â€year study. Journal of Gastroenterology and Hepatology (Australia), 2015, 30, 719-725.	1.4	25
29	Childhood Wheeze Phenotypes Show Less Than Expected Growth in FEV₁ across Adolescence. American Journal of Respiratory and Critical Care Medicine, 2014, 189, 1351-1358.	2.5	75
30	Models for the analysis of repeated continuous outcome measures in clinical trials. Respirology, 2014, 19, 155-161.	1.3	30
31	Making the Most of Clinical Data: Reviewing the Role of Pharmacokinetic-Pharmacodynamic Models of Anti-malarial Drugs. AAPS Journal, 2014, 16, 962-974.	2.2	26
32	Early-Life Risk Factors for Childhood Wheeze Phenotypes in a High-Risk Birth Cohort. Journal of Pediatrics, 2014, 164, 289-294.e2.	0.9	53
33	Population Pharmacokinetics of Intravenous Artesunate: A Pooled Analysis of Individual Data From Patients With Severe Malaria. CPT: Pharmacometrics and Systems Pharmacology, 2014, 3, 1-9.	1.3	18
34	The hope in redefining atopy. Clinical and Experimental Allergy, 2013, 43, 583-585.	1.4	1
35	Altered temporal response of malaria parasites determines differential sensitivity to artemisinin. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 5157-5162.	3.3	172
36	Nonlinear Mixed-Effects Modelling of In Vitro Drug Susceptibility and Molecular Correlates of Multidrug Resistant Plasmodium falciparum. PLoS ONE, 2013, 8, e69505.	1.1	5

#	Article	IF	Citations
37	Assessing the utility of an anti-malarial pharmacokinetic-pharmacodynamic model for aiding drug clinical development. Malaria Journal, 2012, 11, 303.	0.8	42
38	Association analysis of oestrogen receptor beta gene (ESR2) polymorphisms with female pattern hair loss. British Journal of Dermatology, 2012, 166, 1131-1134.	1.4	31
39	Hospitalisation with Infection, Asthma and Allergy in Kawasaki Disease Patients and Their Families: Genealogical Analysis Using Linked Population Data. PLoS ONE, 2011, 6, e28004.	1.1	24
40	Evidence for two independent functional variants for androgenetic alopecia around the androgen receptor gene. Experimental Dermatology, 2010, 19, 1026-1028.	1.4	24
41	Gene-wide association study between the aromatase gene (CYP19A1) and female pattern hair loss. British Journal of Dermatology, 2009, 161, 289-294.	1.4	85
42	Contribution of genes and environment to variation in postural changes in mean arterial and pulse pressure. Journal of Hypertension, 2008, 26, 2319-2325.	0.3	5
43	Baldness and the androgen receptor: the AR polyglycine repeat polymorphism does not confer susceptibility to androgenetic alopecia. Human Genetics, 2007, 121, 451-457.	1.8	62
44	Comparison of antibody responses and parasite clearance in artemisinin therapeutic efficacy studies in Democratic Republic of Congo and Asia. Journal of Infectious Diseases, 0, , .	1.9	1